Next-Gen Diagnostic Device Moves Closer to Commercialization

One of the problems in dealing with many of our most serious diseases is that existing diagnostic procedures are generally:

1. Invasive or unhealthy (i.e. X-rays and other radiology)
2. Expensive
3. Time-consuming
4. Requiring expensive diagnostic equipment

This means that lives are being lost because physicians may be hesitant to commence such diagnostics, or simply the time spent going through current diagnostics delays treatment beyond the point of recovery. The mission of Breathtec Biomedical Inc. (CSE: BTH, OTCQB: BTHCF, Forum) is to save those lives, while helping to conserve valuable healthcare dollars – and to turn a profit in doing so.

As its name implies; Breathtec is involved with breath analysis: analyzing the molecules contained in our expelled breath, and using the data obtained to diagnose some of our most deadly killers or most devastating conditions. This emerging technology can potentially be used to diagnose cancers, Alzheimer’s disease, Parkinson’s disease, liver disease, kidney failure, diabetes, asthma, and tuberculosis.

Revolutionary.

On January 25, 2018; BTH announced that its “V3” device is now ready for testing. In collaboration with Cannabix Technologies, Breathtec’s V3 is designed to operate both independently, and in tandem with existing diagnostic technology, such as the Mass Spectrometer (MS).

The advantages of breath analysis for disease diagnostics are numerous. Being non-invasive/non-intrusive, it is not only highly patient-friendly, it can be repeated as often as necessary. It is cost-effective versus existing diagnostics and delivers rapid results. With other breath-based technology having already received U.S. FDA approval, the Company anticipates a relatively smooth regulatory path for this breath diagnostics device.

The analogy for investors is a simple one. Our fingerprints are a low-tech means for precisely identifying us as individuals. Our “breath print” produces an equally unique biochemical signature – and hi-tech analysis of that signature can reveal the presence of (potentially) numerous maladies.

Breathtec’s CEO, Mike Costanzo emphasized the importance of the Company’s collaboration in advancing development of this prototype:

Breathtec Biomedical remains dedicated to the development of a highly sensitive breathalyzer for disease detection. With our collaboration with Cannabix and the Vancouver Technical Team, we can expedite the testing and analysis of biomarkers related to disease.

Preliminary testing of V3 has shown a correlation in diagnostic results versus the MS. Mass Spectrometer testing is currently “the gold standard in biomarker detection”. This is a crucial finding, as the Company anticipates the Breathtec Disease Detection Breathalyzers being employed as an initial screening procedure, with any positive indicators being subsequently verified through MS testing.

What’s next?

BTH will pursue further development of the V3, taking results from current research and testing to perfect its analysis of the biomarkers contained in our breath. The ultimate goal is a hand-held device for breath-based disease detection, producing highly accurate results that can be applied to the diagnosis of numerous medical conditions. The key in such miniaturization is a “FAIMS” (field asymmetric waveform ion mobility spectrometry) mass spectrometry patent, for which BTH holds an option.

An example of where this Breathalyzer can be applied, and its life-saving potential is with respect to the detection of lung or breast cancer. Dogs have already demonstrated the ability to sniff out cancer in human breath, demonstrating that the potential exists to devise an instrument that can duplicate such detection. The potential savings in human lives (and medical costs) is enormous.



One of the most elementary truths with respect to cancer detection and treatment is that earlier detection greatly improves the odds of a successful outcome. As a fast, cost-effective, non-invasive alternative to existing diagnostics, healthcare providers will have a strong economic incentive to utilize this emerging technology.

The January 25, 2018 announcement that the Company is now moving into the testing of its “V3” device takes Breathtec one significant step closer to commercializing this life-saving (and dollar-saving) diagnostic technology.


FULL DISCLOSURE: Breathtec Biomedical Inc. is a paid client of Stockhouse Publishing.